Compare TANH & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TANH | XBIO |
|---|---|---|
| Founded | 2001 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.9M |
| IPO Year | 2015 | N/A |
| Metric | TANH | XBIO |
|---|---|---|
| Price | $0.99 | $2.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.5K | ★ 35.0K |
| Earning Date | 05-15-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.88 | N/A |
| Revenue | ★ $41,982,988.00 | $2,858,935.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $0.92 | $1.90 |
| 52 Week High | $10.77 | $13.93 |
| Indicator | TANH | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 39.22 |
| Support Level | $0.98 | $1.90 |
| Resistance Level | $1.13 | $2.29 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 36.73 | 40.55 |
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks. The company has two reportable segments: the Consumer Product segment, and the Electric Vehicle (EV) segment.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.